Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721136 | 1.00 | SMYD2 (0.33) | SMYD2CYP3A4 | |
| SCHEMBL723798 | 0.78 | SMYD2 (0.40) | SMYD2CYP3A4 | |
| SCHEMBL10268793 | 0.76 | CYP3A4 (0.34) | SMYD2CYP3A4 | |
| SCHEMBL26558129 | 0.71 | CYP3A4 (0.37) | SMYD2CYP3A4 | |
| SCHEMBL26558088 | 0.70 | TOP2A (0.35) | SMYD2CYP3A4 | |
| SCHEMBL25328586 | 0.70 | CYP2C9 (0.32) | — | |
| SCHEMBL26558108 | 0.68 | SMYD2 (0.34) | SMYD2CYP3A4 | |
| SCHEMBL26558041 | 0.68 | SMYD2 (0.34) | SMYD2CYP3A4 | |
| SCHEMBL13906451 | 0.66 | SMYD2 (0.38) | SMYD2CYP3A4 | |
| SCHEMBL26558166 | 0.66 | TSHR (0.37) | SMYD2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | SMYD2 3643/4885CYP3A4 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.